Sugi Predict

Sugi Predict / Compounds / SCHEMBL517

SCHEMBL517

SCHEMBL517

Cc1ccc(-c2ccccc2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A3 Q01959 4/20 0.50
▸ SLC6A4 P31645 3/20 0.50
▸ SLC6A2 P23975 1/20 0.44
▸ ACHE P22303 1/20 0.43
▸ SCN1A P35498 5/20 0.40
▸ SCN2A Q99250 5/20 0.40
▸ SCN3A Q9NY46 5/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ GRM6 O15303 1/20 0.40
▸ BCAT2 O15382 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9531321 0.88 BCAT2 (0.52) SLC6A3SLC6A4SLC6A2SCN1ASCN2A
SCHEMBL29389473 0.88 BCAT2 (0.52) SLC6A3SLC6A4SLC6A2SCN1ASCN2A
SCHEMBL9402298 0.87 SLC6A3 (0.46) SLC6A3SLC6A4SLC6A2ACHESCN1A
SCHEMBL1665535 0.87 SLC6A3 (0.49) SLC6A3SLC6A4SLC6A2ACHESCN1A
SCHEMBL9373323 0.86 SLC6A3 (0.49) SLC6A3SLC6A4SLC6A2ACHESCN1A
SCHEMBL6900241 0.86 SLC6A3 (0.68) SLC6A3SLC6A4SLC6A2ACHESCN1A
Bromomethane SCHEMBL7011845 0.85 SLC6A3 (0.50) SLC6A3SLC6A4SLC6A2SCN1ASCN2A
Methylamine SCHEMBL28010440 0.85 BCAT2 (0.53) SLC6A3SLC6A4SLC6A2SCN1ASCN2A
SCHEMBL1856687 0.85 SLC6A3 (0.41) SLC6A3SLC6A4ACHEKMT2AMEN1
SCHEMBL3558536 0.84 SLC6A3 (0.48) SLC6A3SLC6A4SLC6A2ACHESCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115108906-A Novel method for preparing 4 '-bromomethyl- [1,1' -biphenyl ] -2-tert-butyl formate 临海市华南化工有限公司 2022-09-27 — — CN claimed
EP-0978503-B1 Synthesis of t-butyl o-(p-tolyl)benzoate by reaction of o-(p-tolyl)benzoic acid with isobutene using acid catalysis CLARIANT GMBH (DE) 2003-05-07 — — EP claimed
US-6369266-B1 Process for producing tert-butyl 4′-methyl-2-biphenylcarboxlate SUMIKA FINE CHEMICALS, CO.,LTD. (JP) 2002-04-09 — — US claimed
EP-1044958-A1 PROCESS FOR PRODUCING tert-BUTYL 4'-METHYL-2-BIPHENYLCARBOXYLATE SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2000-10-18 — — EP claimed
JP-11322676-A — — None — — JP disclosed
US-20240009169-A9 PPARG Modulators for the Treatment of Osteoporosis UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2024-01-11 — — US disclosed
US-20230072933-A1 PPARG Modulators for the Treatment of Osteoporosis SCRIPPS RESEARCH INST (US) 2023-03-09 — — US disclosed
US-20230072933-A1 PPARG Modulators for the Treatment of Osteoporosis SCRIPPS RESEARCH INST (US) 2023-03-09 — — US disclosed
CN-115108906-A Novel method for preparing 4 '-bromomethyl- [1,1' -biphenyl ] -2-tert-butyl formate 临海市华南化工有限公司 2022-09-27 — — CN disclosed
US-10744117-B2 PPARG modulators for the treatment of osteoporosis THE SCRIPPS RESEARCH INSTITUTE (US) 2020-08-18 — — US disclosed
US-10744117-B2 PPARG modulators for the treatment of osteoporosis THE SCRIPPS RESEARCH INSTITUTE (US) 2020-08-18 — — US disclosed
US-20180369196-A1 PPARG Modulators for the Treatment of Osteoporosis UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2018-12-27 — — US disclosed
EP-0446062-A1 C-Linked pyrazole derivatives GLAXO GROUP LIMITED (GB) 1991-09-11 — — EP disclosed
EP-0419048-A2 Substituted pyrimidinones as angiotensin II antagonists MERCK & CO. INC. (US) 1991-03-27 — — EP disclosed
EP-0411766-A1 Substituted quinazolinones as angiotensin II antagonists MERCK & CO. INC. (US) 1991-02-06 — — EP disclosed
EP-0400974-A2 Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists MERCK & CO. INC. (US) 1990-12-05 — — EP disclosed
EP-0400835-A1 Substituted benzimidazoles as angiotensin II antagonists MERCK & CO. INC. (US) 1990-12-05 — — EP disclosed
EP-0324377-A2 Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-19 — — EP disclosed
WO-1989006233-A1 ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-13 — — WO disclosed
EP-0253310-A2 Angiotensin II receptor blocking imidazoles E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-01-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230072933-A1 PPARG Modulators for the Treatment of Osteoporosis PPARG, PPARA, PPARD SLC6A3 4659/4885SLC6A4 4231/4885SLC6A2 4244/4885
US-20180369196-A1 PPARG Modulators for the Treatment of Osteoporosis PPARG, PPARA, PPARD SLC6A3 4659/4885SLC6A4 4231/4885SLC6A2 4244/4885
US-10744117-B2 PPARG modulators for the treatment of osteoporosis PPARG, PPARA, PPARD SLC6A3 4659/4885SLC6A4 4231/4885SLC6A2 4244/4885
US-20240009169-A9 PPARG Modulators for the Treatment of Osteoporosis PPARG, PPARA, PPARD SLC6A3 4659/4885SLC6A4 4231/4885SLC6A2 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.